September 19, 2024
Dublin, Ireland, 18th September 2024 – Afimmune, a clinical stage drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued […]
April 19, 2024
Dublin, Ireland, 19 April 2024: Afimmune announced today its collaborative partnership with Pathway to Cures (P2C) to support the development of Epeleuton as a potential therapeutic […]
November 8, 2023
Dublin, Ireland, 8 November 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that recruitment has commenced in the first clinical […]
September 18, 2023
Dublin, Ireland, 18 September 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted […]
June 19, 2023
Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease […]
June 5, 2023
Dublin, Ireland, 5 June 2023: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology […]
March 29, 2023
Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a […]
January 4, 2023
Afimmune looking to initiate Pivotal study in 2023 Dublin, Ireland, 4 January 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the […]
September 19, 2022
Dublin, Ireland, 19 September 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation […]
July 19, 2022
Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
June 10, 2022
Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
August 26, 2021
Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]